The epidermal growth factor receptor (EGFR) is expressed in the majority of non- small-cell lung cancer (NSCLC). However, only a restricted subgroup of NSCLC patients respond to treatment with the EGFR tyrosine kinase inhibitor (EGFR TKI) gefitinib. Clinical trials have demonstrated that patients carrying activating mutations of the EGFR significantly benefit from treatment with gefitinib. In particular, mutations of the EGFR TK domain have been shown to increase the sensitivity of the EGFR to exogenous growth factors and, at the same time, to EGFR TKIs such as gefitinib. EGFR mutations are more frequent in patients with particular clinical and pathological features such as female sex, nonsmoker status, adenocarcinoma histology, and East Asian ethnicity. A close correlation was found between EGFR mutations and response to gefitinib in NSCLC patients. More importantly, randomized Phase III studies have shown the superiority of gefitinib compared with chemotherapy in EGFR mutant patients in the first-line setting. In addition, gefitinib showed a good toxicity profile with an incidence of adverse events that was significantly lower compared with chemotherapy. Therefore, gefitinib is a major breakthrough for the management of EGFR mutant NSCLC patients and represents the first step toward personalized treatment of NSCLC. © 2011 Carotenuto et al, publisher and licensee Dove Medical Press Ltd.

Optimizing response to gefitinib in the treatment of non-small-cell lung cancer / Carotenuto, P.; Roma, C.; Rachiglio, A. M.; Pasquale, R.; Franco, R.; Antinolfi, G.; Piantedosi, F.; Illiano, A.; Botti, G.; Morabito, A.; Normanno, N.; de Luca, A.. - In: PHARMACOGENOMICS AND PERSONALIZED MEDICINE. - ISSN 1178-7066. - 4:1(2011), pp. 1-9. [10.2147/PGPM.S6626]

Optimizing response to gefitinib in the treatment of non-small-cell lung cancer

Carotenuto P.
Primo
;
Illiano A.;Botti G.;
2011

Abstract

The epidermal growth factor receptor (EGFR) is expressed in the majority of non- small-cell lung cancer (NSCLC). However, only a restricted subgroup of NSCLC patients respond to treatment with the EGFR tyrosine kinase inhibitor (EGFR TKI) gefitinib. Clinical trials have demonstrated that patients carrying activating mutations of the EGFR significantly benefit from treatment with gefitinib. In particular, mutations of the EGFR TK domain have been shown to increase the sensitivity of the EGFR to exogenous growth factors and, at the same time, to EGFR TKIs such as gefitinib. EGFR mutations are more frequent in patients with particular clinical and pathological features such as female sex, nonsmoker status, adenocarcinoma histology, and East Asian ethnicity. A close correlation was found between EGFR mutations and response to gefitinib in NSCLC patients. More importantly, randomized Phase III studies have shown the superiority of gefitinib compared with chemotherapy in EGFR mutant patients in the first-line setting. In addition, gefitinib showed a good toxicity profile with an incidence of adverse events that was significantly lower compared with chemotherapy. Therefore, gefitinib is a major breakthrough for the management of EGFR mutant NSCLC patients and represents the first step toward personalized treatment of NSCLC. © 2011 Carotenuto et al, publisher and licensee Dove Medical Press Ltd.
2011
Optimizing response to gefitinib in the treatment of non-small-cell lung cancer / Carotenuto, P.; Roma, C.; Rachiglio, A. M.; Pasquale, R.; Franco, R.; Antinolfi, G.; Piantedosi, F.; Illiano, A.; Botti, G.; Morabito, A.; Normanno, N.; de Luca, A.. - In: PHARMACOGENOMICS AND PERSONALIZED MEDICINE. - ISSN 1178-7066. - 4:1(2011), pp. 1-9. [10.2147/PGPM.S6626]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/875820
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 5
  • ???jsp.display-item.citation.isi??? ND
social impact